Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
155.00    -1.60 (-1.02%)
Bid:
154.80
Ask:
155.20
Spread: 0.40 (0.258%)
Market Cap: £886.25m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Directorate Change

15 Mar 2022 07:53

RNS Number : 8059E
Elementis PLC
15 March 2022
 

 

 

 

 

15 March 2022Elementis plc

Directorate Changes

Elementis plc (ELM.L) (the "Company"), global specialty chemicals company, today announces the following changes to the Board of Directors:

 

Anne Hyland, Chair of the Audit Committee will retire from the Board at the Company's Annual General Meeting (AGM) on 26 April 2022, consequently Anne will not be seeking re-election at the AGM.

 

Christine Soden will assume the role of Chair of the Audit Committee, effective from the AGM and will remain as Designated Non-Executive Director for workforce engagement. Christine is an existing member of the Audit Committee and has been deemed by the Board to have significant, recent and relevant financial experience with competence in accounting.

 

Dr. Geertrui (Trudy) Schoolenberg has been appointed as a Non-Executive Director with immediate effect and will join the Audit, Nomination and Remuneration Committees. Trudy will assume the role of Senior Independent Director at the conclusion of the Annual General Meeting on 26 April 2022.

 

Trudy has over 30 years' experience of working in the chemicals, engineering and high performance product sectors, including over 20 years with Royal Dutch Shell where she led business strategy and growth plans for Shell Chemicals. As well as strategy and growth experience, Dr Schoolenberg has strong operational knowledge, gained both during her time at Shell and thereafter at Akzo Nobel from 2013-2017 where she was Global Director SRD of Akzo Nobel Decorative Paints.

 

Dr Schoolenberg is a non-executive director of Accsys Technologies plc (AIM and Euronext listed), Supervisory board member of Avantium N.V.(Euronext Amsterdam SmallCap Index) and SPIE SA (Euronext Paris). Trudy previously served as non-executive director and senior independent director at Spirax-Sarco Engineering plc (2012-2021), non-executive director and senior independent director of Low and Bonar plc (2013-2020) and non-executive director of not for profit, The Netherlands Petroleum Stockpiling Agency (COVA) (2011-2021).

Dr Schoolenberg has a Ph.D in Technical Physics from the Delft University of Technology (The Netherlands) and holds a master's degree in Industrial Engineering.

 

Steve Good will remain as Chair of the Remuneration Committee and as a member of the Nomination Committee following the Annual General Meeting.

 

At the conclusion of the AGM, the membership of the Board Committees will be:

 

· Audit Committee: Christine Soden (Chair), Dorothee Deuring and Trudy Schoolenberg

· Remuneration Committee: Steve Good (Chair), Dorothee Deuring, John O'Higgins and Trudy Schoolenberg

· Nomination Committee: John O'Higgins (Chair), Dorothee Deuring, Steve Good, Trudy Schoolenberg and Christine Soden

 

 

 

John O'Higgins, Chair of Elementis, said:

 

 "I am delighted that Trudy is joining the Elementis Board. Trudy's skills and background demonstrate in-depth knowledge of the chemicals sector, global markets, technical innovation and the ESG agenda. She has a strong international perspective and is an experienced Board member with substantial UK Plc experience.

 

We will greatly miss Anne's contribution and commitment to Elementis. Anne leaves with the Board's best wishes and we wish her well for the future. "The Company confirms that there are no other matters requiring disclosure pursuant to LR 9.6.13R (1) to (6) in respect of Trudy Schoolenberg's appointment.

 

 

Laura HigginsGroup Company Secretary020 7067 2999

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAUVVBRUAUOARR
Date   Source Headline
15th Jun 202612:42 pmRNSTransaction in Own Shares
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.